Tieteelliset julkaisut

Tulokset kategoriasta aihe hakusanalla Psykedeeliavusteinen psykoterapia yleisesti. Takaisin


Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions (Garcia-Romeu A, Richards WA, 2018)
Julkaisu:International Review of Psychiatry
Tiivistelmä: Humans have used serotonergic hallucinogens (i.e. psychedelics) for spiritual, ceremonial, and recreational purposes for thousands of years, but their administration as part of a structured therapeutic intervention is still a relatively novel practice within Western medical and psychological frameworks. In the mid-20th century, considerable advances were made in developing therapeutic approaches integrating administration of low (psycholytic) and high (psychedelic) doses of serotonergic hallucinogens for treatment of a variety of conditions, often incorporating psychoanalytic concepts prevalent at that time. This work contributed seminal insights regarding how these substances may be employed with efficacy and safety in targeted therapeutic interventions, including the importance of optimizing set (frame of mind) and setting (therapeutic environment). More recently, clinical and pharmacological research has revisited the effects and therapeutic potential of psychedelics utilizing a variety of approaches. The current article provides an overview of past and present models of psychedelic therapy, and discusses important considerations for future interventions incorporating the use of psychedelics in research and clinical practice.
Yhdiste:Psykedeelit yleisesti
Aihe:Psykedeeliavusteinen psykoterapia yleisesti
Menetelmät:Katsausartikkeli
Otoskoko:0
Muuta:
Tagit:
DOI:https://doi.org/10.1080/09540261.2018.1486289
URL: https://www.tandfonline.com/doi/full/10.1080/09540261.2018.148628...
LinkkiPysyvä linkki julkaisun sivulle tietokannassamme


Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy (Hendricks PS, 2018)
Julkaisu:International Review of Psychiatry
Tiivistelmä: A psychological model of classic psychedelic-assisted psychotherapy informed by contemporary scientific data is presented in this paper. It is suggested that classic psychedelic-occasioned mystical experience is characterized by profound awe, a discrete emotion experienced in the presence of a vast stimulus requiring accommodation of mental structures. Awe, in turn, promotes the small self, a construct that, in the extreme, is analogous to those of unitive experience and ego dissolution. The small self is conceptualized as key to understanding the downstream effects of mystical experience occasioned in the context of classic psychedelic-assisted psychotherapy. With this novel theoretical framework in mind, a number of clinical implications and recommendations are provided so as to advance this incipient field of study.
Yhdiste:Psykedeelit yleisesti
Aihe:Psykedeeliavusteinen psykoterapia yleisesti
Menetelmät:Katsausartikkeli
Otoskoko:0
Muuta:
Tagit:
DOI:https://doi.org/10.1080/09540261.2018.1474185
URL: https://www.tandfonline.com/doi/full/10.1080/09540261.2018.147418...
LinkkiPysyvä linkki julkaisun sivulle tietokannassamme


Psychedelics and music: neuroscience and therapeutic implications (Barrett FS, Preller KH, Kaelen M, 2018)
Julkaisu:International Review of Psychiatry
Tiivistelmä: From the beginning of therapeutic research with psychedelics, music listening has been consistently used as a method to guide or support therapeutic experiences during the acute effects of psychedelic drugs. Recent findings point to the potential of music to support meaning-making, emotionality, and mental imagery after the administration of psychedelics, and suggest that music plays an important role in facilitating positive clinical outcomes of psychedelic therapy. This review explores the history of, contemporary research on, and future directions regarding the use of music in psychedelic research and therapy, and argues for more detailed and rigorous investigation of the contribution of music to the treatment of psychiatric disorders within the novel framework of psychedelic therapy.
Yhdiste:Psykedeelit yleisesti
Aihe:Psykedeeliavusteinen psykoterapia yleisesti
Menetelmät:Katsausartikkeli
Otoskoko:0
Muuta:
Tagit:
DOI:https://doi.org/10.1080/09540261.2018.1484342
URL: https://www.tandfonline.com/doi/full/10.1080/09540261.2018.148434...
LinkkiPysyvä linkki julkaisun sivulle tietokannassamme


Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans (Heal DJ, Gosden J, Smith SL, 2018)
Julkaisu:Neuropharmacology
Tiivistelmä: Psychedelics comprise drugs come from various pharmacological classes including 5-HT2A agonists, indirect 5-HT agonists, e.g., MDMA, NMDA antagonists and κ-opioid receptor agonists. There is resurgence in developing psychedelics to treat psychiatric disorders with high unmet clinical need. Many, but not all, psychedelics are schedule 1 controlled drugs (CDs), i.e., no approved medical use. For existing psychedelics in development, regulatory approval will require a move from schedule 1 to a CD schedule for drugs with medical use, i.e., schedules 2–5.

Although abuse of the psychedelics is well documented, a systematic preclinical and clinical evaluation of the risks they pose in a medical-use setting does not exist. We describe the non-clinical tests required for a regulatory evaluation of abuse/dependence risks, i.e., drug-discrimination, intravenous self-administration and physical dependence liability. A synopsis of the existing data for the various types of psychedelics is provided and we describe our findings with psychedelic drugs in these models. FDA recently issued its guidance on abuse/dependence evaluation of drug-candidates (CDER/FDA, 2017). We critically review the guidance, discuss the impact this document will have on non-clinical abuse/dependence testing, and offer advice on how non-clinical abuse/dependence experiments can be designed to meet not only the expectations of FDA, but also other regulatory agencies. Finally, we offer views on how these non-clinical tests can be refined to provide more meaningful information to aid the assessment of the risks posed by CNS drug-candidates for abuse and physical dependence.
Yhdiste:Psykedeelit yleisesti
Aihe:Päihdekäyttö, Psykedeeliavusteinen psykoterapia yleisesti, haitta-arvio
Menetelmät:Katsausartikkeli
Otoskoko:0
Muuta:
Tagit:
DOI:https://doi.org/10.1016/j.neuropharm.2018.01.049
URL: https://www.sciencedirect.com/science/article/pii/S00283908183005...
LinkkiPysyvä linkki julkaisun sivulle tietokannassamme